In 1992, Morton and colleagues reported that localizing and examining the first draining lymph node from a primary melanoma (the sentinel lymph node; SLN) could predict with remarkable accuracy, those patients who would not have additional nodal disease on completion lymph node dissection. 1 Since then, the prognostic value of this procedure has been validated, in that patients with disease in their SLNs (and with no other known disease) have significantly worse survival than those with SLN-negative disease. One critical question that was not answered in trials examining the prognostic significance of this procedure was whether SLN biopsy (SLNB) could be used to improve the survival of patients with primary melanoma. Several earlier randomized studies that applied elective prophy lactic lymph node dissection (EPLND) to all patients with primary melanoma failed to show an overall survival benefit when compared with observation. 2, 3 However, these failures of EPLND to show a benefit was blamed on the studies being insufficiently powered rather than the null hypothesis being correct.
In 2006, the initial results of the Multicenter Selective Lymphadenectomy Trial (MSLT) trial were published in the New England Journal of Medicine by Morton and co-investigators. 4 This trial was aimed at answering the question of whether selective EPLND (as directed by a positive SLNB) could improve the melanoma speci fic survival of patients with intermediate thickness melanoma compared to simple resection of the primary and subsequent observation (applying lymph node dissection only to those who developed clinicall y evident nodal disease). The final results of this trial (MSLT-I) have now been reported 5 and are essentially the same as the earlier report. In a well-designed and rigorously implemented study, 1,661 patients were randomly assigned in a 2:3 ratio to have resection of melanomas of at least intermediate thickness (>1.2 mm) and then either be followed up for recurrence and survival (with delayed therapeutic lymphadenectomy for those developing a lymph node recurrence), or undergo SLNB at diagnosis and have an EPLND if sampling of the nodes was positive. The primary end point of the trial was melanoma-specific survival and follow up in this report was 10 years. The clear answer from the MSLT I study is that no difference in melanoma-specific survival could be detected between the two arms. Even when patients with the thickest primary melanomas were eliminated (assuming that many of them would already have covert distant metastases), the 10-year melanoma-specific survival was 78% in the observation group and 81% in the SLNB/ EPLND group (P = 0.18). If melanomas with a thickness of 1.0-4.0 mm (the current criterion for intermediate thickness) are considered-and a Cox model applied to correct for small differences between arms in gender, thickness, site, ulceration, etc.-the statistical s ignificance of the difference is even less (P = 0.30).
These results could, and perhaps should, be the end of the story. Additional analyses on overall survival with and without positive SLNs only confirm their utility as a prognostic tool. Furthermore, comparing recurrence-free survival between the randomized arms largely reflects that one group had intact lymph nodes in which recurrence was possible, and the other had already had those removed in the highest risk patients. Perhaps the most complicated analysis is the subset analysis confined to patients with nodal disease in the two arms. In the observation arm, 'node-positive' patients were defined by the pathologically confirmed clinical appearance of melanoma-involved lymph nodes during post-randomization follow up-a goldstandard for nodal involvement. In the SLN group, node-positive patients were defined as those with melanoma in at least one sentinel lymph node where even a single immunohistochemically identified cell is interpreted as positive. This raises the question of the specificity of such a test for identifying node-positive patients and the potential for ascertainment bias in defining the groups. In the final analysis, the percentage of node-positive patients in the two arms is 17.4% and 20.0% for observation versus SLN, respectively. This result in itself was not statistically significant, but allowing up to one in eight patients to be possibly mis allocated (that is, SLN false-positive) is cause for concern when one is doing an analysis of the survival of this small subset. This is important because the melanoma-specific survival in node-positive patients is the sole basis of the main positive conclusion asserted by the authors. In the final study analysis, node-positive patients (defined by the different criteria in the two arms) had better 
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melanoma-specific survival if they had SLNB and EPLND. The hazard ratio was 0.67 (P = 0.04), when only melanomas of intermediate thickness are consideredthere was no difference between arms for thicker melanomas. The analysis of a small subset, the possibility of subtle ascertainment bias, and the borderline statistical signifi cance of this finding casts doubt on this conclusion.
From this study one cannot conclude that no patient with primary melanoma would benefit from a SLN-directed EPLND. One can only say that no benefit could be detected in a well-designed and meticulously executed randomized study of 1,661 patients. To determine more precisely if EPLND can affect survival, MSLT-2 will assess patients who are already defined to have nodal involvement by a positive SLN and they will be randomly assigned to EPLND or ultrasound monitoring and observation. Yet, without the results of that study, one must ask, how has SLNB become the standard of care for inter mediate thickness melanomas? Guidelines for the staging and therapy of melanoma that include SLNB have been widely accepted in the USA, Canada, Europe, Australia, and New Zealand. 6 These guidelines go beyond the current British recommendation that this surgery is a "staging procedure… that … has no proven therapeutic value". 7 Nodal staging has been advocated by some because of the availability of adjuvant interferon-α (IFN) for patients with nodal involvement, yet IFN has not been shown to clearly improve survival of patients with melanoma either. 8 So, an expensive procedure that costs approximately US$10,000-$15,000 9 and without a proven survival benefit is being used to justify the use of a toxic adjuvant that also has no clear survival benefit. Such recommendations cannot represent the best data-driven use of our healthcare dollars. The best current evidence of whether to perform SLNB when a patient and their doctor are faced with a new diagnosis of primary melanoma is provided by the definitive result of MSLT1: "No significant treatment-related difference in the 10-year melanoma-specific survival rate was seen in the overall study population…". 5 Certainly, there is prognostic information in a SLNB, and its use in defining patients for research studies is justifiable. Yet, without additional data showing that it can improve survival, it must be considered an expensive and optional staging tool and understood as such by patients considering this procedure. The MSLT-1 study compared sentinel lymph node biopsy (SLNB) with nodal observation in patients with localized cutaneous melanoma. The final results of the trial-conducted from 1994 to 2002-strongly support using SLNB in staging patients with melanomas ≥1.0 mm in thickness, but the optimal staging approach for thinner melanomas is unanswered. Sentinel lymph node biopsy (SLNB) for the surgical staging of clinically node-negative cutaneous melanoma, which was introduced by Morton et al. in 1992, 1 has been broadly accepted worldwide, albeit with some islands of controversy.
2 Two large prospective evaluations of SLNB were carried out in the years following its i ntroduction -the Sunbelt Melanoma Trial, 3 which involved over 3,600 patients with melanomas ≥1.0 mm undergoing SLNB, and the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1). 4, 5 MSLT-1 is the only randomized trial of SLNB ever conducted; it randomly assigned 2,001 patients in a 60:40 ratio to either SLNB or nodal observation. Patients with positive nodes (found at SLNB or upon recurrence) underwent radical lymphadenectomy. The primary end point was melanoma-specific survival, with secondary end points including relapsefree survival (RFS) and melanoma-specific survival for the subset of node-positive patients. Outcomes in patients with positive sentinel nodes, who underwent early lymphadenectomy, were compared with outcomes in those who underwent delayed lymphadenectomy at the time of nodal relapse. Results of 1,661 patients with melanomas ≥1.2 mm in t hickness were included in the final report.
Supporting a wealth of other data, the MSLT-1 trial confirmed that sentinel node status is the most important prognostic factor for clinically localized melanomas ≥1 mm in thickness. A positive sentinel node was detected in about 20% of patients, and approximately 5% of patients with a negative SLNB developed nodal recurrence. RFS was signifi cantly improved in the SLNB arm, largely due to a much lower rate of regional nodal recurrence than noted in the observation arm. However, melanoma-specific survival was not significantly different for '' …this finding is more than sufficient to justify routine use of the procedure ''
